Bernstein Adjusts Moderna Price Target to $28 From $39, Maintains Market Perform Rating
HSBC Upgrades Moderna(MRNA.US) to Buy Rating, Cuts Target Price to $49
BofA Securities Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $26
TD Cowen Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $30
Wolfe Research Adjusts Moderna Price Target to $20 From $25, Keeps Underperform Rating
William Blair Maintains Moderna(MRNA.US) With Hold Rating
Leerink Partners Maintains Moderna(MRNA.US) With Sell Rating, Cuts Target Price to $23
Leerink Partners Sticks to Their Sell Rating for Moderna (MRNA)
Jefferies Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $30
Redburn Atlantic Adjusts Moderna's Price Target to $52 From $55, Keeps Neutral Rating
Goldman Sachs Adjusts Price Target on Moderna to $35 From $49
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $32
Moderna Is Maintained at Equal-Weight by Morgan Stanley
Moderna Analyst Ratings
RBC Capital Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $32
RBC Cuts Price Target on Moderna to $32 From $40, Keeps Sector Perform Rating
Bernstein Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $39
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Cuts Target Price to $212
Citi Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $40
Moderna Analyst Ratings